Billionaire-backed Ganymed grabs ASCO spotlight with gastric cancer drug

Investigators on the drug say that Ganymed’s IMAB362 “can significantly extend median survival when added to standard chemotherapy–13.2 months vs. 8.4 months–for patients with advanced gastric cancer.”